44
Views
3
CrossRef citations to date
0
Altmetric
Review

Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease

Pages 155-162 | Published online: 09 Jan 2014

References

  • Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest115(4), 957–965 (1999).
  • Ware J, Sherbourne CD. The MOS 36-item short form health survey (SF-36).Conceptual framework and item selection. Med. Care30, 473–483 (1992).
  • Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J.19(2), 217–224 (2002).
  • Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am. J. Respir. Crit. Care Med.155(4), 1283–1289 (1997).
  • Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin. Proc.82(5), 575–582 (2007).
  • Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St George’s Respiratory Questionnaire. Am. Rev. Respir. Dis.145(6), 1321–1327 (1992).
  • Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest127(1), 335–371 (2005).
  • Carone M, Bertolotti G, Anchisi F et al. Analysis of factors that characterize health impairment in patients with chronic respiratory failure. Quality of Life in Chronic Respiratory Failure Group. Eur. Respir. J.13(6), 1293–1300 (1999).
  • Carone M, Jones PW. Health status “quality of life”. In: European Respiratory Monograph: Pulmonary Rehabilitation. Donner CF, Decramer M (Eds). Sheffield, UK, 22–36 (2000).
  • Carone M, Ambrosino N, Bertolotti G et al. Quality of Life Evaluation and Survival Study: a 3-yr prospective multinational study on patients with chronic respiratory failure. Monaldi Arch. Chest Dis.56(1), 17–22 (2001).
  • van der Molen T, Willemse BW, Schokker S et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual. Life Outcomes1(1), 13 (2003).
  • Kocks JW, Tuinenga MG, Uil SM et al. Health status measurement in COPD. The minimal clinically important difference of the Clinical COPD Questionnaire. Respir. Res.7(1), 62 (2006).
  • Antoniu S, Puiu A, Zaharia B, Azoicai D Health-related quality of life and hospitalisations for COPD exacerbations: validity of the Romanian version of the clinical COPD questionnaire. Eur. Respir. J.34(Suppl. 53), 606s (2009).
  • Jones PW, Harding G, Berry P et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J.34(3), 648–654 (2009).
  • Vincken W. Bronchodilator treatment of stable COPD. Long-acting anticholinergics. Eur. Respir. Rev.14(94), 23–31 (2005).
  • Scullion JE. The development of anticholinergics in the management of COPD. Int. J. Chron. Obstruct. Pulmon. Dis.2(1), 33–40 (2007).
  • Wadbo M, Lofdahl CG, Larsson K et al. Effects of formoterol and ipratropium bromide in COPD. A 3-month placebo-controlled study. Eur. Respir. J.20(5), 1138–1146 (2002).
  • Dahl R, Greefhorst LA, Nowak D et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.164(5), 778–784 (2001).
  • Dompeling E, van Schayck CP, Molema J et al. Inhaled beclomethasone improves the course of asthma and COPD. Eur. Respir. J.5(8), 945–952 (1992).
  • Vincken W, van Noord JA, Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur. Respir. J.19(2), 209–216 (2002).
  • Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax61(10), 854–862 (2006).
  • Decramer M, Celli B, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT), a prespecified subgroup analysis of a randomised controlled trial. Lancet374(9696), 1171–1178 (2009).
  • Tashkin DP, Celli B, Kesten S et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur. Respir. J. DOI:10.1183/09031936.00082909 (2009) (Epub ahead of print).
  • Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med.359(15), 1543–1554 (2008).
  • Appleton S, Jones T, Poole P et al. Ipratropium bromide versus long-acting β2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.3, CD006101 (2006).
  • Rennard SI, Stoner JA. Challenges and opportunities for combination therapy in chronic obstructive pulmonary disease. Proc. Am. Thorac Soc.2(4), 391–393 (2005).
  • Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax58(5), 399–404 (2003).
  • Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest112(6), 1514–1521 (1997).
  • Rutten-van Molken M, Roos B, van Noord JA. An empirical comparison of the St George’s Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax54(11), 995–1003 (1999).
  • Tashkin DP, Klein GL, Colman SS, Zayed H, Schonfeld WH. Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy. Am. J. Med.120(5), 435–441 (2007).
  • Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ320(7245), 1297–1303 (2000).
  • Pauwels RA, Lofdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med.340(25), 1948–1953 (1999).
  • Brightling CE, Mckenna S, Hargadon B et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax60(3), 193–198 (2005).
  • Spencer S, Calverley PM, Sherwood Burge P, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.163(1), 122–128 (2001).
  • Calverley PM, Rennard S, Nelson HS et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir. Res.9, 73 (2008).
  • Calverley PM, Boonsawat W, Cseke Z et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J.22(6), 912–919 (2003).
  • Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J.21(1), 74–81 (2003).
  • Mahler DA, Wire P, Horstman D et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.166(8), 1084–1091 (2002).
  • Hanania NA, Darken P, Horstman D et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest124(3), 834–843 (2003).
  • Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet361(9356), 449–456 (2003).
  • Wouters EF, Postma DS, Fokkens B et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax60(6), 480–487 (2005).
  • Celli BR, Macnee W. Standards for the diagnosis and treatment of patients with COPD. A summary of the ATS/ERS position paper. Eur. Respir. J.23(6), 932–946 (2004).
  • Jenkins CR, Jones PW, Calverley PM et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res.10, 59 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.